JIC
EDIT icon

Joel Isaacson & Co’s Editas Medicine EDIT Stock Holding History

Joel Isaacson & Co’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$221K Hold
68,144
– – 0.01% 445
2026
Q1 		$168K Hold
68,144
– – 0.01% 436
2025
Q4 		$140K Buy
+68,144
New +$197K ﹤0.01% 447

Other funds holding EDIT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Joel Isaacson & Co's EDIT Position: Q2 2026 in Review

Joel Isaacson & Co held its Editas Medicine (EDIT) position steady in Q2 2026 at 68,144 shares worth $221K. The position accounts for 0.01% of the portfolio, ranked #445.

Joel Isaacson & Co first reported a position in EDIT in Q4 2025 and has held it in 3 quarters since. 79 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Joel Isaacson & Co held 68,144 shares of Editas Medicine worth $221K as of Q2 2026.
  • Joel Isaacson & Co left its Editas Medicine share count unchanged in Q2 2026.
  • Editas Medicine made up 0.01% of Joel Isaacson & Co's portfolio in Q2 2026, its #445 holding.
  • Joel Isaacson & Co first reported a position in Editas Medicine in Q4 2025 and has held it in 3 quarters since.
  • 79 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Joel Isaacson & Co's 13F filing for Q2 2026, filed 4 Aug 2026.